PubMed Health⌕ Search

Biomedical subjects

F Lotstra

Publications and source records attributed to F Lotstra.

54 records · Page 3Linked to original sources

General anesthesia after neuroleptic malignant syndrome.

The neuroleptic malignant syndrome (NMS) is an uncommon and potentially lethal complication of therapy with neuroleptics characterized by pallor, hyperthermia, and extrapyramidal signs (Delay and Deniker, 1968). Malignant hyperthermia (MH) is a rare but often fatal complication of general anesthesia characterized by hyperpyrexia and muscle rigidity, but not related to neuroleptic therapy. For both syndromes, NMS and MH, a common pathophysiology has been considered (Meltzer, 1973; Itoh, 1977; Caroff, 1980). These two syndromes may also be clinically indistinguishable from "acute lethal catatonia" characterized by fever, muscular hypertonicity, and stupor, first described by Stauder in 1934. We now report a case in whom NMS appeared following neuroleptic treatment for a psychotic depressive syndrome. After remission from the NMS, the patient underwent general anesthesia nine times for electroconvulsive therapy (ECT) without ill effect. This case supports the theory of distinct pathogenic mechanisms for both NMS and MH.

Anesthesia, General↗

Immunohistochemical evidence for cholecystokinin-like peptides in neuronal cell bodies of the rat spinal cord.

Cholecystokinin-like immunoreactivity has been demonstrated by radioimmunoassay and immunocytochemistry in the spinal cord of various mammals, in particular in nerve fibers of the superficial layers of the posterior column, but had not been detected in neuronal cell bodies. We report immunohistochemical evidence for the presence of a group of cholecystokinin-containing neuronal cell bodies in the lumbar spinal cord of the rat. This group of cells is only visualized after direct injection of colchicine into the spinal cord and is located near the central canal in the intermedio-medial nucleus of area X of Rexed.

Animals↗

Coexistence of cholecystokinin and oxytocin-neurophysin in some magnocellular hypothalamo-hypophyseal neurons.

The existence of cholecystokinin in the posterior hypophysis and its hypothalamic origin have been unequivocally demonstrated. Immunocytochemical evidence is presented for the coexistence of gastrin-cholecystokinin and oxytocin-neurophysin I immunoreactivities in some magnocellular neurons of the supraoptic and paraventricular nuclei both in rat and bovine hypothalamus.

Animals↗

Cholecystokinins in the central nervous system and neurohypophysis.

Research on digestive peptides in brain started in 1975 with the discovery of peptides of the gastrin-cholecystokinin family in the brain of various vertebrates. Cholecystokinin octapeptide is largely distributed in the brain and neurohypophysis and its mapping has recently been reported by various authors. An up to data table summarizing CCK mapping is included. Cholecystokinin coexists with dopamine in some mesencephalic neurones and with oxytocin in some hypothalamic neurones. CCK immunoreactive fibers have been detected in the anterior commissura and in the corpus callosum especially after its surgical sectioning. CCK immunoreactive cell bodies are present in the nucleus septum lateralis, the nucleus of the bed of the stria terminalis and the nucleus preopticus medialis especially after direct colchicine injection into the cerebral hemispheres. Cholecystokinin is of importance in structures related to various physiological functions such as motricity, sensory mechanisms, endocrine and limbic systems. Consequently it should be interesting to study cholecystokinins in neurological disorders and in psychiatric conditions.

Animals↗

Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat.

The distribution of gastrin-cholecystokinin-like peptide(s) is reported in brain and hypophysis of the rat. The unlabeled peroxidase-antiperoxidase complex immunohistochemical technique was used. Controls of specificity for various peptides were studied with solid-phase absorption. Colchicine treatment was necessary to obtain positivity in many neuronal cell bodies. In addition to their already known distribution, gastrin-cholecystokinins containing neural cell bodies and fibers were present in olfactory structures, in various preoptic and hypothalamic nuclei (except in mamillary bodies), in mesencephalic nucleus linearis rostralis, and in A-10, A-9, and A-8 regions of Dahlström and Fuxe, which include substantia nigra. From previous investigations and the present distribution study, it can be inferred that, although most of the brain material consists of cholecystokinin, gastrins may also be present in hypothalamo-posthypophyseal magnocellular cells, in nucleus tractus solitarii, and in the dorsal horn of the spinal cord. The distribution of positive cell bodies in the peripheral part of the paraventricular nucleus and in the dorsal part of the supraoptic nuclei in the hypothalamus is similar to that of oxytocin neurons. The localization of positive cell bodies in A-10, A-9, and A-8 regions of Dahlström and Fuxe is similar to that of dopaminergic neurons. The mesencephalic concentration of cell bodies and the wide distribution of fibers in striatal, hypothalamic, septal, and other hemispheric structures together with thick positive fibers in the medial forebrain bundle is consistent with the existence of ascending mesencephalic pathways, including the nigrostriate pathway.

Amygdala↗

Distribution of immunoreactive cholecystokinin in the human hippocampus.

The distribution of cholecystokinin immunoreactive (CCK-IR) nerve cell bodies and processes is reported in the human hippocampus by using the peroxidase-antiperoxidase technique of Sternberger. The CCK-immunoreactivity occurs in three major classes of interneurons: small (10-20 microns) horizontal multipolar neurons of the alveus and stratum oriens; small vertically oriented bipolar or multi-polar neurons in the stratum oriens and stratum pyramidale of Ammon's horn, layers II and III of the subicular system and the entorhinal area; large (20-35 microns) bipolar neurons in the hilus. Each region of the hippocampus is distinct in its CCK-IR nerve fibers content. Those fibers are particularly abundant around pyramidal cells of the CA2 and CA3 subfields of the Ammon's horn and around granular cells suggesting synaptic interaction between the CCK nerve terminals and glutamate neurons of these two regions. No CCK-IR fiber is detected in the fimbria and only a few number of CCK-IR beaded fibers are seen in the angular bundle. These anatomical data suggest that CCK interacts in the functional circuitry of the human hippocampus.

Cholecystokinin↗

[Biological models of schizophrenia: an update].

This paper is a review of the principal, currently proposed, biological models of schizophrenia. The convergence of recent neurobiological studies indicates that schizophrenia may be a neurodevelopmental and progressive disorder with multiple biochemical abnormalities involving dopamine, serotonin, glutamate and gamma-aminobutyric acidergic systems. In post-mortem tissue, structural abnormalities and alterations in synaptic connectivity have been observed in the intracortical circuitry of the prefrontal dorsal cortex. These morphological modifications could be sequelae of earlier environmental insults and genetic processes. There are probably multiple susceptibility genes, each of small effect, which act in conjunction with environmental factors: obstetric abnormalities, intra-uterine infection and abnormal nutrition. Candidate identified genes could influence neurodevelopment, synaptic plasticity and neurotransmission. If schizophrenia is clearly related to an abnormality of early brain development, the clinical expression of the illness itself is delayed typically for about two decades after birth. A similar delayed onset is also observed in the secondary psychosis associated with metachromatic leukodystrophy, a genetic disease affecting myelin. Schizophrenia is a term reserved for idiopathic cases of chronic psychosis. Strictly speaking, schizophrenia is a syndrome. There are no established laboratory tests, neuro-imaging studies, electrophysiological paradigms or neuropsychological testing batteries that can explicitly confirm this behavioural disorder to the exclusion of symptomatology: what physicians diagnose as schizophrenia today may prove to be a cluster of different illnesses, with similar and overlapping symptoms. The diagnosis criteria of the various DSM reflect the American psychiatrists' concern for establishing a consensus classification preserving a wider definition of schizophrenia or more precisely of the schizophrenic disorder. One can presume that research work established from too numerous and insufficiently specific variables doesn't permit the definition of one or several aetiologies. We hope that one day all schizophrenia will be correlated to one precise causal factor permitting the optimal targeting of interesting therapeutic approaches. The multiplicity of concepts and models reflects our questioning.

Dopamine↗

[No hypofrontality in schizophrenia demonstrated by positron emission tomography].

We studied cerebral glucose metabolism, using Positron Emission Tomography (PET) and (F-18) fluorodeoxyglucose, in 15 young schizophrenic patients compare to 15 age-matched healthy volunteers. The PET investigation was made in a quiet room with a dimly light. Each subject remained in a supine resting state with eyes closed. Results failed to demonstrate any differences in glucose utilization between schizophrenic patients and control subjects, as far as absolute or relative, left and right values are concerned. Besides, variability of metabolic values was significantly higher in schizophrenics than in controls.

Adult↗

[Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].

INTRODUCTION: Many authors have described these last years the difficulty to establish a differential diagnosis between schizophrenia and frontotemporal dementia. However treatment and prognosis of these two separate diseases are not the same. Schizophrenia is a chronic syndrome with an early onset during teenage or young adulthood period and the major features consist of delirious ideas, hallucinations and psychic dissociation. However a large variety of different symptoms describes the disease and creates a heterogeneous entity. The diagnosis, exclusively defined by clinical signs, is then difficult and has led to the research of specific symptoms. These involve multiple psychological processes, such as perception (hallucinations), reality testing (delusions), thought processes (loose associations), feeling (flatness, inappropriate affect), behaviour (catatonia, disorganization), attention, concentration, motivation (avolition), and judgement. The characteristic symptoms of schizophrenia have often been conceptualised as falling into three broad categories including positive (hallucination, delision), negative (affective flattening, alogia, avolition) and disorganised (poor attention, disorganised speech and behaviour) symptoms. No single symptom is pathogonomonic of schizophrenia. These psychological and behavioural characteristics are associated with a variety of impairments in occupational or social functioning. Cognition impairments are also associated with schizophrenia. Since the original clinical description by Kraepelin and Bleuler, abnormalities in attentional, associative and volitional cognitive processes have been considered central features of schizophrenia. Long term memory deficits, attentional and executive dysfunctions are described in the neurocognitive profile of schizophrenic patients, with a large degree of severity. The pathophysiology of schizophrenia is not well known but may be better understood by neuronal dysfunctions rather than by a specific anatomical abnormality. Frontotemporal lobar degeneration (FTLD) is one of the most common causes of cortical dementia. FTLD is associated with an anatomical atrophy that can be generalised, with a frontotemporal or focal lobar predominance. Histologically there is severe neuronal loss, gliosis and a state of spongiosis. In a minority of case Pick cells and Pick bodies are also found. The usual clinical features of FTLD are divided in three prototypic syndromes: frontotemporal dementia (FTD), progressive non-fluent aphasia (PA) and semantic dementia (SD). FTD is the most common clinical manifestation of FTLD. FTD is first characterised by profound alteration in personality and social conduct, characterised by inertia and loss of volition or social disinhibition and distractibility. There is emotional blunting and loss of insight. Speech output is typically economical, leading ultimately to mutism, although a press of speech may be present in some overactive, disinhibited patients. Memory is relatively preserved in the early stage of the disease. Cognitive deficits occur in the domains of attention, planning and problems solving, whereas primary tools of language, perception and spatial functions are well preserved. PA is an initial disorder of expressive language, characterised by effortful speech production, phonologic and grammatical errors. Difficulties in reading and writing also occur but understanding of word meaning is relatively well preserved. In SD a severe naming and word comprehension impairment occur on the beginning in the context of fluent, effortless, and grammatical speech output. There is also an inability to recognise the meaning of visual percepts. The clinical syndromes of FTLD are associated with the brain topography of the degeneration. So considerable clinical overlap can exist between schizophrenia and FTLD and the object of the following case report is to remind the difficulty to make a differential diagnosis between these two pathologies. CASE REPORT: A 34 year old non-married man is admitted in mental health district of a general hospital for behavioural disturbances that include repeated aggressions towards his family. At initial interview visual and auditives hallucinations are described. The patient doesn't care about these abnormalities and a poverty of speech is observed. The affects, globally blunted, show some degree of sadness however. The patient's birth and early development were unremarkable. At the age of 26, the patient dismissed from his job because of poor performance and absenteeism. He spent a lot of time watching TV, showed poverty of speech and become sometimes angry and violent without an explanation. He was hospitalised for several months and a schizophrenia including predominant negative features, hallucinations and delusion was diagnosed. He was treated with bromperidol, could go back to home and was followed by a general practitioner for 8 years. The patient had a stereotyped way of life during these years with a poor communication and little activity. During the months preceding the current hospitalisation, these characteristics and avolition emphasised, urinary incontinence appeared. The patient receives risperidone 8 mg/day associated with citalopram 40 mg/day during several months of hospitalisation. No significant evolution is observed regarding apathic and stereotyped way of live. The capacity of communication remains very poor. Neurocognitive assessments reveal multiple and severe dysfunctions. Memory, executive and attentional tasks are extremely disturbed. Physical and neurological examinations reveal an isolated bilateral Babinski sign. Cerebral scanner and magnetic resonance show bifrontal atrophy and PET scan is normal. There are no significant abnormalities found on blood and urine samples and on lumbar puncture. The patient is sent to a chronic neuropsychiatric hospital and the treatment is stopped. One year later, a comparative evaluation is realised. The general clinical state shows no evolution. Neurocognitive assessments are repeated and severe dysfunctions are observed with more perseverations. DISCUSSION: A diagnosis of FTLD for this patient can be discussed regarding clinical features, neurocognitive testings and neuroradiological findings. Schizophrenia is a major differential diagnosis. Psychotic symptoms like hallucinations and age of onset are essential observations for the diagnosis of schizophrenia but can not exclude FTLD. Memory, intellectual functions, executive and attentional abilities may all be disturbed in schizophrenia and FTLD. Cerebral abnormalities well established in schizophrenia are lateral ventricles enlargements. Frontal lobar atrophy is a major argument for FTLD and is only a sporadic finding in schizophrenic populations. Schizophrenia and FTLD could be comorbid diseases by several ways. CONCLUSION: A differential diagnosis between schizophrenia and FTLD is difficult to establish. Schizophrenia is a heterogeneous disease with a large variety of cognitive dysfunctions. Neurocognitive tools may improve our knowledge of schizophrenia.

Adult↗

Substance P neurons in the human hippocampus: an immunohistochemical analysis in the infant and adult.

An analysis of the distribution of substance P immunoreactive nerve cell bodies and fibres is given for infant and adult human hippocampus by using the peroxidase-antiperoxidase technique of Sternberger. The description covers the substance P distribution in the area dentata, the Ammon's horn, the subicular complex and the entorhinal cortex. Each region shows a specific pattern in its substance P immunoreactivity. In general, the hippocampal neurons occur in three major classes of interneurons: large (20-35 microns) horizontal bipolar or multipolar neurons in the alveus, in the deep part of the subicular complex, the entorhinal cortex, and in the white matter of the angular bundle; small (10-20 microns) and large (20-35 microns) vertically oriented bipolar or multipolar neurons in the stratum oriens, in the stratum pyramidale of the Ammon's horn, and in the deep part of the subicular complex and the entorhinal cortex; large (20-35 microns) multipolar neurons in the hilus. Substance P immunoreactive fibres are particularly abundant around pyramidal cells of the CA2 and CA3 subfields of the Ammon's horn and around granule cells of the area dentata. They are also detected in the fimbria and angular bundle. Comparative study of the infant and adult hippocampus reveals no variation in the area dentata and Ammon's horn except that substance P immunoreactive fibres are more abundant in the molecular layer of the area dentata in adults. In contrast, a far more extensive number of substance P immunoreactive cell bodies are detected in the deep layers of the subicular complex and the entorhinal cortex, as well as in the white matter of the angular bundle in infants aged between three and 12 months old. This rich substance P immunoreactive network raises questions concerning its function within the human hippocampus.

Adult↗

[Apropos of the 18th case of bismuth encephalopathy recognized in Belgium].

The authors present a typical case of bismuth encephalopathy detected in 1982. The patient was given oral insoluble bismuth salts for 20 years. Blood bismuth level was regularly measured (twice a year). No pathologic level was ever noted before she developed the intoxication. Up to now, only few reports are known in Belgium. Measures to prevent this encephalopathy are discussed.

Aged↗

[Neurobiology of schizophrenia].

Summarizing the most interesting data obtained in schizophrenia by the genetic, morphological and psychopharmacological studies, the authors try to take stock of the two main physiopathological process involved in this disorder, as to say, modifications in the limbic structures anatomy and chemical disturbances in different neurotransmitter system.

Brain↗

[Delirium or acute confusional state in elderly persons].

Delirium or acute confusional state is a common neuropsychiatric syndrome in later life. Failure to recognise delirium and treat the underlying organic condition may have fatal consequences. In delirium the main aspects of cognition, thinking, perception and memory are all disordered to some degree. A global disorder of attention is invariably present and may include illusions and hallucinations. Disturbances in the sleep-wake cycle and abnormalities of the psychomotor activity are essential features. Hypoactive and hyperactive states are reported. Some patients have a mixed picture, with swing back and forth between apathy and agitation. Its onset is acute and its duration is brief (less than one month). Typically, the severity of the symptoms fluctuates during the daytime with peaks at night. The adequate treatment of delirium presupposes that the syndrome has been diagnosed and that its underlying causes have been identified.

Acute Disease↗

[Decrease in the frontal-superobasal metabolic ratio in unipolar depression].

Cerebral frontal glucose metabolism was investigated in 12 unipolar depressed patients and compared to these of 12 healthy volunteers using Positron Emission Tomography (PET) and (F18) fluorodeoxyglucose. The PET investigation was made in a quiet room with a dimly light and each subject remained in a resting state with closed eyes. Results show a decreased in a frontal superobasal calculated ratio in depressed patients compared to control subjects for left and for right values. This reduction indicates an imbalance between the frontal and the superobasal region. This imbalance could relate to some particular depressive symptom profile.

Adult↗